Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Selection of a high activity ribozyme against cytostatic drug resistance-associated glypican-3 using an in vitro assay containing total tumor RNA

Cancer Gene Therapy volume 6, pages 263–270 (1999)Cite this article

Abstract

We tested 11 hammerhead ribozymes for their ability to bind and cleave RNA transcripts of the cytostatic drug resistance-associated glypican-3-encoding gene (GPC3, MXR7, OCI-5). To select the optimum target sequence, the activity of each hammerhead ribozyme was tested in a short in vitro assay using truncated RNA substrates without time-consuming cloning procedures. Glypican-3-derived RNA was cleaved effectively by 3 of 11 hammerhead ribozymes. One of these, the hammerhead ribozyme Rz967, recognized the GUC sequence at nucleotides +965 to +967 of the open reading frame of the glypican-3-encoding mRNA. Rz967 cleaved in vitro-transcribed fragments derived from glypican-3 mRNA (nucleotides +803 to +1036) most efficiently. Cleavage efficiency was confirmed by a rapid in vitro assay using full-length total tumor cell RNA. We were able to demonstrate that this new in vitro assay is suitable for the selection of hammerhead ribozymes that have the capability to cleave glypican-3-encoding mRNA in human tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Institute of Pathology, Humboldt University Berlin, Berlin, Germany

    Anke Wichert, Per Sonne Holm, Manfred Dietel & Hermann Lage

Authors
  1. Anke Wichert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Per Sonne Holm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manfred Dietel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hermann Lage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hermann Lage.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wichert, A., Holm, P., Dietel, M. et al. Selection of a high activity ribozyme against cytostatic drug resistance-associated glypican-3 using an in vitro assay containing total tumor RNA. Cancer Gene Ther 6, 263–270 (1999). https://doi.org/10.1038/sj.cgt.7700045

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700045

Keywords

This article is cited by

Search

Advanced search

Quick links